Partner Content Partner Content 2nd Hit ID Summit Why prioritise your hit discovery game? Finding the right chemical start points is crucial to help you save time and costs in the long run.
R&D Partner Content Unlocking the Potential of Targeting the Innate Immune Syste... Ready to Catalyze the Next Wave of Inflammasome Therapies?
Partner Content Partner Content 5th Oligonucleotides for CNS Summit The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism
R&D Partner Content 2nd ADC & Novel Conjugates Partnering & Investment Summit Refine your strategy, sharpen your positioning, and meet the right partners - all at the most efficient networking event of the ADCconference calendar
R&D Partner Content Network With EHS Professionals - EHS&S for Biopharma West Advancing Biosafety & Sustainability in R&D & Manufacturing
R&D Partner Content Welcome to the 2nd Raw Materials for Cell & Gene Therapy Sum... Streamline Supply Chain Communications to Optimize Phase Appropriate QC Testing, Comparability & GMP Manufacturing of Raw Materials...
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.